Shorts
0:40
Ziftomenib Moves Toward Phase 3 in Frontline AML
3 days ago
by
Amer Zeidan, MBBS
0:36
Ziftomenib Combo Shows Acceptable Induction Safety in AML
4 days ago
by
Amer Zeidan, MBBS
0:55
Frontline Promise With Ziftomenib Combo in AML
5 days ago
by
Amer Zeidan, MBBS
0:42
Why Young Doctors Can't Forget the Basics
5 days ago
by
Yan Ji, MD
0:41
Is Over-Treatment the Hidden Problem in Modern Cancer Care?
5 days ago
by
Bruna Pellini, MD
0:20
Dr Pellini Busts Lung Cancer Myths
6 days ago
by
Bruna Pellini, MD
1:29
How to Use AI to Keep Up With 350,000+ Medical Papers
6 days ago
by
Pallav K. Mehta, MD
0:39
Advancing Innovation Through Community Oncology Care
12 days ago
by
Fran Gregory, PharmD, MBA
0:25
Why Women's Cancer Symptoms are Ignored
13 days ago
by
Narjust Florez, MD
1:05
Dr Jani Talks Updates in Early-Onset Colorectal Cancer
13 days ago
by
Chinmay Jani, MD
1:07
Dr Jani Talks Research in Early-Onset Lung Cancer
14 days ago
by
Chinmay Jani, MD
0:37
Linking Technology, Outcomes, and Advanced Care
19 days ago
by
Fran Gregory, PharmD, MBA
0:36
Better Operations = Better Patient Experience
19 days ago
by
Derek Burns, PharmD(+1 more)
0:44
How Minor Drug Tweaks Are Revolutionizing Cancer Patient Care
19 days ago
by
Jessica White, PharmD
0:33
Could Localized Injections Be the Secret Weapon Against Lung Cancer?
25 days ago
by
Estelamari Rodriguez, MD, MPH
0:40
Can We Turn Cold Tumors Hot to Fight Lung Cancer?
25 days ago
by
Estelamari Rodriguez, MD, MPH
0:38
Why Outcomes Data Matter More Than Ever
a month ago
by
Fran Gregory, PharmD, MBA
0:38
A Unique Inhibitor: Why This Cancer Drug is Different
a month ago
by
Sara A. Hurvitz, MD
1:12
Dr Kalinsky Talks Updates in Lobular Carcinoma
a month ago
by
Kevin Kalinsky, MD, MS
0:32
Could a Breakthrough in Pancreatic Cancer Change Breast Cancer Treatment?
a month ago
by
Paolo Tarantino, MD
0:40
Why ADCs Are Changing Breast Cancer Treatment
a month ago
by
Paolo Tarantino, MD
0:45
Can Targeted Therapies Redefine DLBCL Treatment?
a month ago
by
Sonali M. Smith, MD
0:37
Don’t Reinvent the Wheel: Peer Insights for Advanced Therapies
a month ago
by
Fran Gregory, PharmD, MBA
0:45
New Breast Cancer Trial Results: Omitting Surgery is Safe
a month ago
by
Jana de Boniface, MD
0:40
Glossary Break: PFS vs OS
a month ago
by
Sabrina Serani
0:50
Glossary Break: All About Biomarkers
a month ago
by
Sabrina Serani
0:25
ASCO 2026: Brain Fog & Prostate Cancer Treatment
a month ago
by
Sabrina Serani
0:30
Dr Herzberg Talks Updates in KRAS-Mutant NSCLC
a month ago
by
Benjamin Herzberg, MD
0:42
The Future of Breast Cancer Treatment: Escalation vs De-Escalation
a month ago
by
Javier Cortés, MD, PhD
1:04
Glossary Break: All About Liquid Biopsies
a month ago
by
Sabrina Serani
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
How a Virtual Behavioral Health Program Is Reaching Patients With Cancer Who Need It Most
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5